{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Percutaneous+Coronary+Intervention",
    "query": {
      "condition": "Percutaneous Coronary Intervention"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 280,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Percutaneous+Coronary+Intervention&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:46:45.666Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00060554",
      "title": "A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myocardial Infarction",
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "fondaparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "heparin",
          "type": "DRUG"
        },
        {
          "name": "percutaneous coronary intervention (PCI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Schering-Plough",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-11-03",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 8,
      "location_summary": "Ocala, Florida • Chicago, Illinois • Worcester, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060554"
    },
    {
      "nct_id": "NCT02594501",
      "title": "Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Angina, Stable",
        "Angina, Unstable",
        "Anticoagulants"
      ],
      "interventions": [
        {
          "name": "COBRA PzF",
          "type": "DEVICE"
        },
        {
          "name": "Drug Eluting Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CeloNova BioSciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 996,
      "start_date": "2016-02-05",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-26",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 22,
      "location_summary": "Newark, Delaware • Jacksonville, Florida • Melbourne, Florida + 18 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02594501"
    },
    {
      "nct_id": "NCT06358508",
      "title": "Sapphire 3 CTO Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Coronary Disease",
        "Myocardial Ischemia",
        "Heart Diseases",
        "Arteriosclerosis",
        "Cardiovascular Diseases",
        "Chronic Total Occlusion",
        "Chronic Total Occlusion of Coronary Artery"
      ],
      "interventions": [
        {
          "name": "Sapphire 3 Coronary Dilatation Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "OrbusNeich",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2024-11-06",
      "completion_date": "2025-10-21",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 12,
      "location_summary": "Stanford, California • Torrance, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06358508"
    },
    {
      "nct_id": "NCT00165035",
      "title": "Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "CoStar Paclitaxel Drug Eluting Coronary Stent System",
          "type": "DEVICE"
        },
        {
          "name": "TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cordis US Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1701,
      "start_date": "2005-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-08-04",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165035"
    },
    {
      "nct_id": "NCT03416920",
      "title": "A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "Wellframe",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 167,
      "start_date": "2018-02-12",
      "completion_date": "2019-08-20",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03416920"
    },
    {
      "nct_id": "NCT03218787",
      "title": "XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Lesions"
      ],
      "interventions": [
        {
          "name": "XIENCE",
          "type": "DEVICE"
        },
        {
          "name": "DAPT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2047,
      "start_date": "2017-07-19",
      "completion_date": "2020-09-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 101,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03218787"
    },
    {
      "nct_id": "NCT00046228",
      "title": "A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "abciximab placebo; reteplase placebo, abciximab, abciximab",
          "type": "DRUG"
        },
        {
          "name": "Abciximab; reteplase; abciximab placebo; abciximab",
          "type": "DRUG"
        },
        {
          "name": "abciximab; reteplase placebo; abciximab placebo; abciximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 2461,
      "start_date": "2002-08",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-07-31",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Covina, California • Modesto, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046228"
    },
    {
      "nct_id": "NCT06909565",
      "title": "Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Percutaneous Coronary Intervention",
        "Peripheral Endovascular Intervention"
      ],
      "interventions": [
        {
          "name": "Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6000,
      "start_date": "2025-07-23",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 96,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 87 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06909565"
    },
    {
      "nct_id": "NCT05727059",
      "title": "Magenta Elevate™ EFS in High-Risk PCI Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "High-risk Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "The Elevate™ System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Magenta Medical Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-05-08",
      "completion_date": "2024-01-02",
      "has_results": false,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05727059"
    },
    {
      "nct_id": "NCT01218828",
      "title": "Prevention of Contrast Renal Injury With Different Hydration Strategies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contrast Medium-induced Nephropathy"
      ],
      "interventions": [
        {
          "name": "LVEDP -Based hydration strategy",
          "type": "OTHER"
        },
        {
          "name": "Standard hydration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2010-10",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-05-22T07:46:45.666Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218828"
    }
  ]
}